MELISSA HOEGG: Open Payments
NPI 1205458130 · OWENSBORO, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$686 in 36 payments from 15 companies in 2025. Trend: 2023 $520 · 2024 $257 · 2025 $686
Food & beverage: $623Education: $63
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 15 | $252 |
| Celgene Corporation | 4 | $83 |
| AstraZeneca Pharmaceuticals LP | 2 | $61 |
| E.R. Squibb & Sons, L.L.C. | 2 | $43 |
| GlaxoSmithKline, LLC. | 2 | $42 |
| Gilead Sciences, Inc. | 2 | $36 |
| Iovance Biotherapeutics, Inc. | 1 | $24 |
| ADC THERAPEUTICS AMERICA, INC. | 1 | $21 |
| Aveo Pharmaceuticals, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
Products named: XTANDI, REBLOZYL, IBRANCE, ENHERTU, OPDUALAG, OJJAARA, INLYTA, Trodelvy.
Industry payments across KY — which companies pay providers there.
